Multiple pathogenic antigens (Polyclonal IgG targets)

This target represents the broad spectrum of antigenic epitopes recognized by the polyclonal IgG antibodies found in therapeutic immunoglobulin preparations. It is not a single molecular entity but a heterogeneous collection of viral, bacterial, and fungal antigens, as well as various self-antigens (Source: PMID: 25601003). The therapeutic utility of this "target" lies in the ability of pooled human IgG to provide passive immunity through the neutralization of pathogens and toxins (Source: StatPearls). Additionally, the interaction of these antibodies with the host's immune system—via Fc receptors and complement proteins—allows for the treatment of autoimmune and inflammatory disorders (Source: NIH). This multi-target approach is the hallmark of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) therapies. By targeting a wide repertoire of epitopes, these drugs can address complex pathologies that single-target monoclonal antibodies may not fully cover.

Other names

Polyclonal IgG epitope repertoireIVIG target antigensPathogen-derived antigensHeterogeneous polyclonal IgG repertoire

The mechanism involves the binding of polyclonal IgG antibodies to a diverse array of pathogenic epitopes, resulting in the neutralization of viruses and toxins, enhancement of phagocytosis through opsonization, and modulation of inflammatory pathways via Fc receptor saturation and complement inhibition (Source: StatPearls, "Intravenous Immunoglobulin").